Author: Austin Nguyen; Julianne K David; Sean K Maden; Mary A Wood; Benjamin R Weeder; Abhinav Nellore; Reid F Thompson
Title: Human leukocyte antigen susceptibility map for SARS-CoV-2 Document date: 2020_3_26
ID: k3y8tpps_10
Snippet: We were further interested in whether certain regions of the SARS-CoV-2 proteome showed differential presentation by the MHC class I pathway. Accordingly, we surveyed the distribution of antigen presentation capacity across the entire proteome, highlighting its most conserved peptide sequences (Figure 4 ). Throughout the entire proteome, HLA-A and HLA-C alleles exhibited the relative largest and smallest capacity to present SARS-CoV-2 antigens, r.....
Document: We were further interested in whether certain regions of the SARS-CoV-2 proteome showed differential presentation by the MHC class I pathway. Accordingly, we surveyed the distribution of antigen presentation capacity across the entire proteome, highlighting its most conserved peptide sequences (Figure 4 ). Throughout the entire proteome, HLA-A and HLA-C alleles exhibited the relative largest and smallest capacity to present SARS-CoV-2 antigens, respectively. However each of the three major class I genes exhibited a very similar pattern of peptide presentation across the proteome (Supplementary Figure S3) . We additionally note that peptide presentation appears to be independent of estimated time of peptide production during viral life cycle, with indistinguishable levels of peptide presentation of both early and late SARS-CoV-2 peptides (Supplementary Figure S4 ). CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- antigen presentation and differential presentation: 1, 2, 3
- antigen presentation and entire proteome: 1, 2, 3, 4, 5
- antigen presentation and International license: 1
- antigen presentation and life cycle: 1, 2, 3, 4
- antigen presentation and major class: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antigen presentation and MHC class: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antigen presentation and pathway MHC class: 1, 2, 3, 4, 5, 6
- antigen presentation and peptide presentation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antigen presentation capacity and major class: 1, 2, 3
- antigen presentation capacity and MHC class: 1, 2
- antigen presentation capacity and pathway MHC class: 1
- cc NC ND International license and estimate time: 1, 2, 3, 4, 5, 6
- cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cc NC ND International license and major class: 1
- cc NC ND International license and MHC class: 1
- entire proteome and MHC class: 1, 2, 3
- estimate time and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9
- International license and life cycle: 1, 2
- International license and major class: 1, 2
Co phrase search for related documents, hyperlinks ordered by date